Natural HDAC Inhibitors for Epigenetic Combating of Cancer Progression PDF

Natural HDAC Inhibitors for Epigenetic Combating of Cancer Progression PDF

Name:
Natural HDAC Inhibitors for Epigenetic Combating of Cancer Progression PDF

Published Date:
01/01/2023

Status:
[ Active ]

Description:

Publisher:
CRC Press Books

Document status:
Active

Format:
Electronic (PDF)

Delivery time:
10 minutes

Delivery time (for Czech version):
200 business days

SKU:
natural-hdac-inhibitors-for-epigenetic-combating-of-cancer-progression_2847473

Choose Document Language:
39.60 €
Need Help?
ISBN: 9781000848328

Natural HDAC Inhibitors for Epigenetic Combating of Cancer Progression deals only with HDAC inhibitors from natural origins including bacteria, fungi, marine organisms and, notably, from diverse plant sources. This book is unique in the sense that it is the only book that discusses wholly and solely HDAC inhibitors of natural origin in the context of cancer chemotherapy. Another peculiar feature of this book is that it debates futuristic nanotechnology approaches for escalating the aqueous solubility, cancer cell uptake, bioavailability and other favourable pharmacological parameters, including the cytotoxicity of natural HDAC inhibitors against cancer cells.

The major features of this book encompass

General compendium of HDAC inhibitors with deep emphasis on the toxicity issues of synthetic HDAC inhibitors

Various groups of natural HDAC inhibitors, their representatives and premier sources

Cyclic tetrapeptides of natural origin and their importance as cancer chemotherapeutic agents

Hydroxamates and depsipeptides from natural sources and their promising role in cancer therapy

Natural flavonoids, their HDAC inhibitory tendency and marvellous anticancer activity

Non-flavonoid natural HDAC inhibitors and their pleasing cytotoxic effects towards cancer models

Combined therapy involving natural flavonoids with other anticancer molecules for synergistic and additive benefits against cancer models

Non-flavonoid HDAC inhibitors and conventional drugs in collaborative mode against aggressive malignancies

Nanotechnology-based delivery of natural HDAC inhibitors for greater therapeutic efficacy over traditional combinatorial therapy

This book is highly beneficial to university professors and research scholars working on epigenetic therapeutics in general, and natural HDAC inhibitors in particular. This book is equally important to medical oncologists, biochemistry as well as pharmacy candidates and students of master's and undergraduate level with a desire to do a doctorate on HDACs, natural HDAC inhibitors, HDAC inhibitor (natural)-based combinatorial chemotherapy and delivery of these inhibitors selectively to tumour sites through revolutionary nanotechnological tactics.

Author: Shabir Ahmad Ganai


Edition : 1.
Number of Pages : 171
Published : 01/01/2023
isbn : 9781000848328

History


Related products

Ecological Engineering: Principles and Practice
Published Date: 09/25/2003
48.00 €
Healthcare Management Dictionary
Published Date: 06/30/2003
13.20 €
Introduction to Sustainable Energy Transformation
Published Date: 01/01/2022
82.50 €

Best-Selling Products

AAMI/ISO 10993-1:2003
Published Date: 12/01/2003
Biological Evaluation of Medical Devices Part 1: Evaluation and Testing
26.40 €
AAMI/ISO 10993-1:2009 Erratum
Published Date: 06/10/2013
Erratum for Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
AAMI/ISO 10993-1:2009/(R)2013
Published Date: 09/03/2009
Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process; Includes Erratum (2013)
AAMI/ISO 10993-1:2018
Published Date: 04/27/2020
Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
82.50 €
AAMI/ISO 10993-10:2010/(R)2014
Published Date: 09/04/2010
Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization
82.50 €
AAMI/ISO 10993-11:2006/(R)2014
Published Date: 10/19/2006
Biological evaluation of medical devices - Part 11: Tests for systemic toxicity